Jeunemaitre X Gimenez-Roqueplo AP, 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 3822 – 3828. ( https://doi.org/10
Search Results
David Taïeb, Abhishek Jha, Giorgio Treglia, and Karel Pacak
Roeliene C Kruizinga, Wim J Sluiter, Elisabeth G E de Vries, Bernard A Zonnenberg, Cornelis J Lips, Anouk N A van der Horst-Schrivers, Annemiek M E Walenkamp, and Thera P Links
VHL disease include renal cysts and renal cell cancers (RCC), pheochromocytomas, pancreatic cysts, and pancreatic neuroendocrine tumors (pNET), as well as epididymal and broad ligament cystadenomas ( Lonser et al . 2003 , Maher et al . 2011 ). VHL
Ales Vicha, David Taieb, and Karel Pacak
predisposition to malignant pheochromocytomas and paragangliomas . Human Molecular Genetics 23 2440 – 2446 . ( doi:10.1093/hmg/ddt639 ). Cervera AM Bayley JP Devilee P McCreath KJ 2009 Inhibition of succinate dehydrogenase dysregulates histone
G Eisenhofer, T-T Huynh, K Pacak, F M Brouwers, M M Walther, W M Linehan, P J Munson, M Mannelli, D S Goldstein, and A G Elkahloun
H , Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53 679 –683. Kees UR , Ford J, Watson M, Murch A, Ringner M, Walker RL & Meltzer P 2003 Gene expression
Anne-Paule Gimenez-Roqueplo, Mercedes Robledo, and Patricia L M Dahia
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib . Annals of Oncology 32 S621. ( https://doi.org/10.1016/j.annonc.2021.08.702 ) Ben
Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, and Ashley Grossman
.1038/ng.2953 ) Averbuch SD Steakley CS Young RC Gelmann EP Goldstein DS Stull R Keiser HR 1988 Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine . Annals
Jay S Fonte, Jeremyjones F Robles, Clara C Chen, James Reynolds, Millie Whatley, Alexander Ling, Leilani B Mercado-Asis, Karen T Adams, Victoria Martucci, Tito Fojo, and Karel Pacak
gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 92 3822 – 3828 . doi:10.1210/jc.2007-0709 . Bhatia KS Ismail MM Sahdev A Rockall AG Hogarth
Alberto Cascón, Lucía Inglada-Pérez, Iñaki Comino-Méndez, Aguirre A de Cubas, Rocío Letón, Jaume Mora, Mónica Marazuela, Juan Carlos Galofré, Miguel Quesada-Charneco, and Mercedes Robledo
Dear Editor: Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare neuroendocrine tumors that arise from the adrenal medulla or from the extra-adrenal sympathetic and parasympathetic paraganglia respectively. Now we know that more than 30% of
Ruth T Casey, Benjamin G Challis, Alison Marker, Deborah Pitfield, Heok K Cheow, Ashley Shaw, Soo-Mi Park, Helen L Simpson, and Eamonn R Maher
, we report a further case of a malignant PGL in a 46-year-old man with a succinate dehydrogenase complex flavoprotein subunit A ( SDHA ) germline mutation (c.91C > T, p.Arg31*). In the case we describe, following the initial surgical removal of a left
Esther Korpershoek, Nanne K Kloosterhof, Angelique Ziel-van der Made, Hanneke Korsten, Lindsey Oudijk, Jan Trapman, Winand N M Dinjens, and Ronald R de Krijger
were involved in writing the paper and had final approval of the submitted and published versions. References Adjalle R Plouin PF Pacak K Lehnert H 2009 Treatment of malignant pheochromocytoma . Hormone and Metabolic Research 41 687
